Scholarlink

<p>Drug-induced liver injury (DILI) is a primary cause of drug attrition, associated with over 1000 medications and accounting for 32% of marketed drugs withdrawn due to toxicity. This has created an urgent demand for high-accuracy computational methods predicting DILI risk early in the drug development pipeline. We developed X-DILiver, a predictive framework built on the largest DILI-annotated dataset to date. We used data augmentation to improve model robustness and address class imbalance. A library of 312 machine learning models was created using various algorithms and molecular features, and then an optimized ensemble strategy was applied. The final model is an ensemble of two extreme gradient boosting models and seven recurrent neural networks. It achieved an accuracy (ACC) of 0.64 and a Matthew’s correlation coefficient (MCC) of 0.33 on the Tanimoto-filtered external test dataset, and an ACC of 0.64 and an MCC of 0.38 on the scaffold-unique external test dataset, outperforming all other publicly available DILI prediction models. While this performance improvement is significant, this accuracy reflects ongoing challenges in DILI prediction. X-DILiver represents a valuable advancement that can assist in DILI risk assessment during drug discovery, serving as a reliable tool to predict DILI potential, thereby accelerating and improving drug discovery safety. To facilitate broad access, X-DILiver is accessible via <a href="http://xdiliver.lile.bio">http://xdiliver.lile.bio</a>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

X-DILiver: an ensemble learning framework for predicting drug-induced liver injury

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月17日

查看全文
  • Jingyu Lee,
  • Myeong-Sang Yu,
  • Yunhyeok Lee,
  • Hyun Jung Nam,
  • Kwang-Seok Oh,
  • Jidon Jang,
  • Hyang-Mi Lee,
  • Dokyun Na

摘要

Drug-induced liver injury (DILI) is a primary cause of drug attrition, associated with over 1000 medications and accounting for 32% of marketed drugs withdrawn due to toxicity. This has created an urgent demand for high-accuracy computational methods predicting DILI risk early in the drug development pipeline. We developed X-DILiver, a predictive framework built on the largest DILI-annotated dataset to date. We used data augmentation to improve model robustness and address class imbalance. A library of 312 machine learning models was created using various algorithms and molecular features, and then an optimized ensemble strategy was applied. The final model is an ensemble of two extreme gradient boosting models and seven recurrent neural networks. It achieved an accuracy (ACC) of 0.64 and a Matthew’s correlation coefficient (MCC) of 0.33 on the Tanimoto-filtered external test dataset, and an ACC of 0.64 and an MCC of 0.38 on the scaffold-unique external test dataset, outperforming all other publicly available DILI prediction models. While this performance improvement is significant, this accuracy reflects ongoing challenges in DILI prediction. X-DILiver represents a valuable advancement that can assist in DILI risk assessment during drug discovery, serving as a reliable tool to predict DILI potential, thereby accelerating and improving drug discovery safety. To facilitate broad access, X-DILiver is accessible via http://xdiliver.lile.bio.